PMID- 27821228
OWN - NLM
STAT- MEDLINE
DCOM- 20170703
LR  - 20181202
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 45
IP  - 11
DP  - 2016 Nov 8
TI  - [Abnormality of TOP2A expression and its gene copy number variations in 
      neuroblastic tumors].
PG  - 748-754
LID - 10.3760/cma.j.issn.0529-5807.2016.11.002 [doi]
AB  - Objective: To detect TOP2A protein expression and gene copy number alterations, 
      and to analyze related clinical and pathological implications in pediatric 
      neuroblastic tumors (NT). Methods: Immunohistochemistry was used to detect TOP2A 
      protein expression. Fluorescence in situ hybridization (FISH) was used to detect 
      numerical aberrations of TOP2A. Results: TOP2A protein was expressed in 
      59.1%(52/88) of cases, which was associated with differentiation (P=0.006), Ki-67 
      index (P<0.01) and MKI (P=0.001). Twenty-eight cases (35.0%, 28/88) showed TOP2A 
      gene amplification, which was correlated with the age (P<0.01), clinical stage 
      (P=0.028), high risk group (P=0.001), Ki-67 index (P=0.040) and differentiation 
      (P=0.014). Survival analysis showed that TOP2A expression was related to survival 
      rate. Multivariate analyses showed that TOP2A expression was an independent 
      predictor for poor prognosis (P=0.010). Conclusions: More than half of the cases 
      show TOP2A expression, which is more likely associated with NB, high Ki-67 index 
      and high MKI. Cases with TOP2A expression have shorter survivals and poorer 
      prognosis. TOP2A amplification is seen in 35% and likely occurs in patients older 
      than 18 months and at advanced INSS stages (Ⅲ and Ⅳ). As a target of the 
      anthracycline-based adjuvant drugs, TOP2A test can be used to select patient with 
      NT for the therapy.
FAU - Chen, J M
AU  - Chen JM
AD  - Department of Pathology, Capital Medical University, Beijing 100069, China.
FAU - Zhou, C J
AU  - Zhou CJ
FAU - Ma, X L
AU  - Ma XL
FAU - Guan, D D
AU  - Guan DD
FAU - Yang, L Y
AU  - Yang LY
FAU - Yue, P
AU  - Yue P
FAU - Gong, L P
AU  - Gong LP
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Poly-ADP-Ribose Binding Proteins)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
RN  - EC 5.99.1.3 (TOP2A protein, human)
SB  - IM
MH  - Age Factors
MH  - Antigens, Neoplasm/*genetics/metabolism
MH  - Breast Neoplasms
MH  - DNA Copy Number Variations
MH  - DNA Topoisomerases, Type II/*genetics/metabolism
MH  - DNA-Binding Proteins/*genetics/metabolism
MH  - Female
MH  - *Gene Amplification
MH  - *Gene Dosage
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Infant
MH  - Neoplasms/*genetics/metabolism/pathology
MH  - Neuroblastoma/*genetics/metabolism/mortality/pathology
MH  - Poly-ADP-Ribose Binding Proteins
MH  - Survival Analysis
EDAT- 2016/11/09 06:00
MHDA- 2017/07/04 06:00
CRDT- 2016/11/09 06:00
PHST- 2016/11/09 06:00 [entrez]
PHST- 2016/11/09 06:00 [pubmed]
PHST- 2017/07/04 06:00 [medline]
AID - 10.3760/cma.j.issn.0529-5807.2016.11.002 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2016 Nov 8;45(11):748-754. doi: 
      10.3760/cma.j.issn.0529-5807.2016.11.002.